Whitehawk Therapeutics Inc. has announced its transition into an Antibody-Drug Conjugate $(ADC)$-focused company, highlighting significant advancements in their ADC platform technology. The presentation outlines the company's strategy, which includes targeting established tumor biology with clinically validated, broadly overexpressed tumor targets. Whitehawk is focusing on high-potential large cancer indications, including lung and ovarian cancers, and aims to leverage their advanced ADC technology for minimal off-target toxicity and greater stability. The company anticipates advancing all three investigational new drugs (INDs) to the clinic by mid-2026. Their portfolio includes assets targeting PTK7, MUC16, and SEZ6. The presentation also highlighted the CPT113 platform, which features advanced ADC architecture with a novel TOPO1 payload and highly stable linker design. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.